Related by context. All words. (Click for frequent words.) 70 CR# vcMMAE 70 alvespimycin 70 PXD# 70 Annamycin 70 vascular disrupting agent 70 advanced carcinoid 69 L Annamycin 69 Archexin 69 PEG SN# 69 Perifosine 68 JAK inhibitor 68 FOLOTYN ® 68 Carfilzomib 68 Proxinium TM 68 relapsed leukemia 68 Symadex 68 Panzem 68 Guanilib 68 phase IIb clinical 67 AEG# 67 anticancer compound 67 Sym# 67 Panzem R 67 MGCD# [001] 67 OXi# 67 Exherin TM 67 investigational humanized monoclonal antibody 67 metaglidasen 67 Aplidin 67 BZL# 67 Dapagliflozin 67 Panzem R NCD 66 PDX pralatrexate 66 oral prodrug 66 IRX 2 66 delafloxacin 66 JAK1 66 MEK inhibitors 66 radiation sensitizer 66 mertansine 66 Azedra TM 66 OncoVEX GM CSF 66 Mipomersen 66 BiovaxID TM 66 IMA# 66 huC# DM4 66 2 methoxyestradiol 66 TACI Ig 66 ganetespib 66 Voreloxin 66 MEK inhibitor RDEA# 66 AP# [003] 66 seliciclib CYC# 66 Curaxin 66 novel peptide 66 Cannabinor 66 PSN# [002] 66 R roscovitine 66 Sapacitabine 66 mitogen activated ERK kinase 66 CEQ# 66 Fx #A 66 anti amnesic 66 AQ4N 66 Nanobody 65 Azedra 65 targeted radiotherapeutic 65 R#/MEM # 65 YONDELIS 65 compound perifosine 65 IAP inhibitors 65 Xanafide 65 Curaxin CBLC# 65 Traficet EN 65 CYT# 65 Hedgehog Pathway Inhibitor 65 RGB # 65 GRN#L 65 OvaRex R 65 Pimavanserin 65 Angiocept 65 Squalamine 65 HGS ETR1 65 refractory gout 65 torezolid phosphate 65 TBC# 65 Bezielle 65 Romidepsin 65 LEP ETU 65 phase IIa clinical 65 ATL# [001] 65 CCX# 65 Tarvacin TM 65 Zybrestat 65 vascular disrupting agents 65 investigational monoclonal antibody 65 BAY #-# 65 Cloretazine ® 65 Lu AA# 65 ENMD # 65 DOS# 65 KRN# 65 elotuzumab 65 PI3K/Akt pathway inhibitor 65 CYC# 65 ELACYT 65 IAP inhibitor 65 obatoclax 65 Tesetaxel 64 Factor VIIa 64 Phase #b/#a clinical 64 trastuzumab DM1 T DM1 64 Cetrorelix 64 BRIM2 64 PDE4 inhibitor 64 JAK2 inhibitor 64 receptor tyrosine kinase inhibitor 64 tiapamil 64 Safinamide 64 otelixizumab 64 MDV# 64 tubulin inhibitor 64 histone deacetylase HDAC inhibitor 64 Ceflatonin 64 CA4P 64 Cloretazine 64 CBLC# 64 DXL# 64 zanolimumab 64 proteasome inhibitor 64 Aganocide 64 PNP inhibitor 64 Pazopanib 64 Aplidin R 64 INCB# [001] 64 hypoxia activated prodrug 64 Aurora Kinase 64 relapsed multiple myeloma 64 CB2 selective receptor agonist 64 leading oral taxane 64 IMC A# 64 CYT# potent vascular disrupting 64 myelofibrosis 64 tanespimycin 64 CCR9 antagonist 64 Personalized Immunotherapy 64 ALN TTR 64 Solazed TM 64 MEK inhibitor 64 Hematide TM 64 ATL/TV# 63 fosbretabulin 63 forodesine 63 HQK 63 IL# PE#QQR 63 therapeutic monoclonal antibody 63 HuMax CD4 63 mapatumumab 63 Aurora kinase 63 Enzastaurin 63 leukemia AML 63 novel anticancer 63 Alocrest 63 anticoagulant reversing agent 63 pan HDAC inhibitor 63 Troxatyl 63 Talactoferrin 63 selective androgen receptor modulator 63 Virulizin ® 63 OHR/AVR# 63 targeting CD# 63 Omacetaxine 63 TELINTRA 63 ZK EPO 63 Tyrima 63 SNT MC# 63 Phase Ib study 63 INCB# [002] 63 epothilone 63 CK # novel 63 bardoxolone 63 MLN# 63 EP #R 63 depsipeptide 63 Aflibercept 63 BNC# 63 REOLYSIN ® 63 multi kinase inhibitor 63 candidate deforolimus 63 Elesclomol 63 pseudobulbar affect PBA 63 HER2 positive metastatic breast 63 myeloproliferative disorders 63 proteasome inhibitors 63 voreloxin 63 PrevOnco 63 CD3 monoclonal antibody 63 pomalidomide 63 ThermoDox R 63 myelofibrosis polycythemia vera 63 sodium Injection 63 tafamidis 63 XL# XL# XL# 63 PSMA ADC 63 elacytarabine 63 reslizumab 63 PI3 kinase inhibitors 63 Talabostat 63 INCB# [003] 63 CRLX# 63 romidepsin novel 63 OMP #M# 63 OvaRex ® MAb 63 cancer immunotherapies 63 VitiGam 63 XL# XL# 63 sorafenib tablets 63 Elagolix 63 Azixa 63 HuMax EGFr 62 Trofex 62 NP2 Enkephalin 62 liposomal formulation 62 cannabinor 62 eltrombopag 62 entinostat 62 systemic RNAi therapeutic 62 Bortezomib 62 Phase IIa clinical 62 Quinamed 62 MAGE A3 ASCI 62 TRAIL receptor antibodies 62 Bicifadine 62 Amrubicin 62 isoform selective 62 glucagon receptor 62 anti leukemic 62 EndoTAG TM -1 62 signal transduction inhibitor 62 PLK1 SNALP 62 acetonide FA 62 generation Hsp# inhibitor 62 dextofisopam 62 XmAb# 62 humanized monoclonal antibody 62 TRO# 62 orally bioavailable 62 Ceflatonin R 62 Epratuzumab 62 HuLuc# 62 PRT# 62 Neuradiab 62 EOquin 62 compound AEZS 62 XL# [003] 62 PRTX 62 cMET 62 multitargeted 62 ISIS # 62 trial evaluating PRX# 62 Phase Ib clinical 62 OMP #R# 62 Radezolid 62 inhibit metastasis 62 VA# [002] 62 next generation URAT1 62 TG# [003] 62 Hsp# inhibitor 62 investigational pan BCR 62 oxidative stress inducer 62 apricitabine ATC 62 AAG geldanamycin analog 62 JAK inhibitors 62 angiogenesis inhibitor 62 including eniluracil ADH 62 indibulin 62 small molecule activator 62 candidate CRLX# 62 sapacitabine 62 Aganocide ® 62 GALNS 62 BN# [002] 62 ALN PCS 62 Phase 2a clinical 62 PRX # 62 BiTE antibody 62 Blinatumomab 62 Luteinizing Hormone Releasing Hormone 62 sodium glucose cotransporter 62 Sphingomab 62 Onconase 62 compound PMX # 62 Triapine 62 PEP# [003] 62 #ME# 62 non nucleoside HCV 62 Akt inhibitor 62 Pathway Inhibitor 62 Reolysin 62 SUTENT ® 62 IMiDs R 62 GRN# 62 Zemiva TM 62 LibiGel ® 62 HSP# inhibitor 62 sodium thiosulfate STS 62 investigational hepatitis C 62 polymerase inhibitors 62 Tamibarotene 62 Diamyd ® 62 kinase inhibition 62 Alzhemed TM 62 forodesine hydrochloride 62 tosedostat 62 Harbor BioSciences 62 VAPRISOL 62 cediranib 62 Phase #/#a trial 62 pralatrexate 62 CRD5 62 XL# anticancer compounds 62 cancer neuroendocrine tumor 62 IMC #B 62 Myelofibrosis 62 generation proteasome inhibitor 62 Golimumab 62 ZYBRESTAT 62 TKM ApoB 62 Maxy G# 62 glucokinase activator 62 tesetaxel 62 Daclizumab 62 Phase Ib clinical trials 62 Hsp# Inhibitor 62 RhuDex ® 62 non nucleoside inhibitor 62 Phase IIb clinical trials 62 Cloretazine R 62 Serdaxin 62 small molecule thrombopoietin 62 CD# antibody [001] 62 OMAPRO 62 riociguat 62 SAR# [004] 61 registrational trial 61 Darinaparsin 61 Trofex TM 61 lorvotuzumab mertansine 61 E1 INT TM 61 ALN TTR# 61 herpetic keratitis 61 Cethrin R 61 RAV# 61 ALN VSP 61 cell lymphoma CTCL 61 Metastatic Melanoma 61 ThGRF 61 MKC# MT 61 ONCONASE R 61 Vicinium TM 61 Aurexis 61 Nanobody ® 61 selective modulator 61 preclinically 61 Phase #b/#a 61 SinuNase 61 targets Galectin receptors 61 ocular formulation 61 VEGFR2 inhibitor 61 DAVANAT 61 HCD# [002] 61 oncolytic vaccine 61 TLK# 61 Thiarabine 61 NXL# 61 ANG# 61 TÎ ² 4 61 anticancer agent 61 selective kinase inhibitor 61 telomerase therapeutic 61 Androxal TM 61 Alpharadin 61 ProLindac TM 61 LY# [003] 61 OXIGON TM 61 Exelixis XL# 61 Clavis Pharma 61 Anavex #-# 61 SAI EGF 61 tezampanel 61 PEGylated 61 PS# [001] 61 Fibrillex TM 61 Cintredekin Besudotox 61 elesclomol 61 epothilones 61 Ambrisentan 61 HGS# 61 BiTE 61 AVN# [001] 61 Glufosfamide 61 polycythemia vera PV 61 multicenter Phase II 61 GLYX 61 GW# [003] 61 Pralatrexate 61 epithelial tumors 61 Randomized Phase 61 EVIZON TM squalamine lactate 61 class mGluR5 inhibitor 61 rxRNA 61 TKB# 61 Allovectin 7 61 Triolex 61 Phase 2b Clinical Trial 61 PI3K inhibitor 61 ENMD 61 Phase III Pivotal 61 davunetide intranasal AL 61 Phase 2a 61 MKC# MKC# PP 61 5 HT6 receptor 61 Celacade TM technology 61 BRAF inhibitor 61 Tovaxin ® 61 oncology therapeutics 61 Sudhir Agrawal D.Phil 61 rNAPc2 61 blinatumomab 61 myeloproliferative diseases 61 Phase IIa trial 61 Phase Ib II 61 dirucotide 61 PORxin TM 61 gallium containing 61 Denufosol 61 Nexavar ® 61 oral proteasome inhibitor 61 Genasense ® oblimersen 61 phase Ib 61 Panzem NCD 61 TOCOSOL Camptothecin 61 Angiolix 61 Exelixis compounds 61 ALK inhibitor 61 Ziopharm 61 protein kinase inhibitor 61 LE SN# 61 CXB# 61 relapsed refractory multiple myeloma 61 pertuzumab 61 GVAX ® 61 Dalbavancin 61 axitinib 61 kidney urologic 61 drug GAP #B# 61 Bavituximab 61 novel topoisomerase 61 talactoferrin 61 ara C 61 ON #.Na 61 MAXY G# 61 drug pipeline TAFA# 61 diabetic nephropathy 61 BrachySil TM 61 Darusentan 61 immunomodulatory 61 orally administered inhibitor 61 vemurafenib 61 TRIOLEX 61 GSK # 61 mGluR5 NAM 61 PKC# 61 generation URAT1 inhibitor 61 CCX# B 61 Aviptadil 61 cilengitide 61 Alfacell proprietary ribonuclease 61 ZFP Therapeutic 61 MGd 61 pharmacokinetic PK study 61 Cyclooxygenase Inhibiting Nitric Oxide 61 vosaroxin 61 Hepatocellular Carcinoma HCC 61 mGluR2 NAM 61 siRNA therapeutics 61 rhIGFBP 3 61 Telbivudine 61 CINOD 61 enzastaurin 61 Phase Ib 61 AA amyloidosis 61 Pyridorin 61 humanized anti 61 Dacogen injection 61 atacicept 61 ZYBRESTAT fosbretabulin 60 HCV protease inhibitor 60 Hedgehog pathway inhibitor 60 Apoptone 60 pralatrexate injection folate analogue 60 enhance ApoA 60 HGS ETR2 60 A3 adenosine receptor 60 LHRH antagonist 60 Shigamabs ® 60 Kamada AAT 60 nucleoside analog 60 #D#C# 60 L BLP# 60 demonstrated antitumor activity 60 anti CD3 monoclonal 60 virus HCV protease inhibitor 60 PROVENGE sipuleucel T 60 mTOR inhibitors 60 PANVAC VF 60 Anti Tumor 60 MCSP respectively 60 tesmilifene 60 Maribavir 60 DCVax R 60 PCK# 60 chemopreventive agent 60 generation antisense 60 molecular imaging radiopharmaceutical 60 Antiangiogenic 60 Behcet uveitis 60 nicotinic alpha 7 60 Meets Primary Endpoint 60 diarrhea predominant irritable 60 ulimorelin 60 Chrysalin 60 AKT inhibitor 60 Epidermal Growth Factor Receptor 60 Hsp# inhibition 60 NEUMUNE 60 Intravenous CP 60 immunotherapeutic agent 60 Cloretazine R VNP#M 60 Vidofludimus 60 allosteric modulator 60 GAP #B# 60 HDL Selective Delipidation 60 hematological malignancies 60 histone deacetylase HDAC inhibitors 60 antisense drug 60 modified glutathione analog 60 polysaccharide polymer 60 LE DT 60 Iluvien ® 60 CD# CEA 60 LymphoStat B belimumab 60 antiangiogenic activity 60 small molecule defensin 60 refractory acute myeloid 60 triggers apoptosis programmed 60 Elotuzumab 60 Phase IIb trials 60 novel histone deacetylase 60 Vernakalant 60 Epothilones 60 MAP# 60 ARRY # 60 Dasatinib 60 EFAPROXYN 60 XYOTAX TM 60 protein kinase inhibitors 60 Apaziquone 60 Gleevec resistant 60 HspE7 60 volociximab 60 EOquin TM 60 histone deacetylase inhibitor 60 essential thrombocythemia ET 60 Neo Kidney Augment 60 Ridaforolimus 60 preclinical 60 XL# XL# XL# XL# 60 compound INCB# 60 Romiplostim 60 Silodosin 60 oral ghrelin agonist 60 LAF# 60 eniluracil 60 Relivar 60 PEG PAL 60 ANAVEX #-# [003] 60 IgG1 monoclonal antibody 60 Lisofylline LSF 60 CD# monoclonal antibody 60 targeted radiotherapeutics 60 noninfectious uveitis 60 SERMs 60 CINQUIL 60 BioNumerik 60 ThermoDox ® clinical 60 Chemokine Therapeutics 60 DAVANAT R 60 novel immunomodulatory 60 Ceftaroline 60 triphendiol 60 rALLy clinical trial 60 MTP inhibitor 60 NASDAQ ALTH biopharmaceutical 60 TPI ASM8 60 PEGylated interferon 60 KNS # 60 immunotherapeutics 60 SinuNase TM 60 Menerba 60 THR beta agonist 60 eculizumab 60 registrational 60 OMNARIS HFA 60 oral Azacitidine 60 HCV protease inhibitors 60 polycythemia vera essential thrombocythemia 60 systemic anaplastic large 60 oxypurinol 60 Myocet 60 lintuzumab SGN 60 Advaxis Phase 60 RhuDex 60 E2F Decoy 60 Antisense 60 IMGN# 60 radezolid 60 targeted antifolate 60 NPC 1C 60 selective immunoproteasome inhibitor 60 romidepsin 60 Vitaxin 60 Tezampanel 60 apoptosis inducer 60 pancreatic carcinoma 60 personalized immunotherapy 60 Solazed 60 panobinostat 60 Seliciclib 60 secondary hyperparathyroidism 60 Tanespimycin 60 Zemiva ™ 60 vidofludimus 60 Tasimelteon 60 MAb 60 MyVax R 60 GEM OS2 60 ILUVIEN ® 60 ospemifene 60 registrational trials 60 kinase inhibitor 60 Albugon 60 partial agonist 60 investigational drug 60 Tumour Vascular Disrupting Agent 60 BMS# 60 IIa trial 60 vaccine GRNVAC1 60 Intarcia 60 CCR5 antagonist 60 fibrotic disease 59 Randomized Double blind 59 Lupus Nephritis 59 PEGylated interferon beta 1a 59 Tarvacin 59 Microplasmin 59 Asentar 59 Muraglitazar 59 recurrent glioblastoma multiforme 59 Ophena 59 Ophena TM 59 acyclovir Lauriad R 59 nanopharmaceutical 59 torezolid 59 Laquinimod 59 Chronic Lymphocytic Leukemia CLL 59 histamine dihydrochloride 59 Celator 59 GSK '# 59 QLT# 59 RNAi Therapeutic 59 CORT # 59 Clinical Trial Results 59 lumiliximab 59 Vandetanib 59 phase IIb trial 59 BAL# [002] 59 KSP inhibitor 59 modulator SERM 59 INS# [001] 59 MBP# [001] 59 SMT C# 59 ZEVALIN ® 59 epigenetic therapies 59 APOPTONE 59 Phase 1b clinical trials 59 romazarit 59 superficial bladder cancer 59 Vicriviroc 59 Pyridorin TM 59 MGCD# [002] 59 Afatinib 59 gefitinib Iressa 59 Oral NKTR 59 antiangiogenesis 59 PD LID 59 Linaclotide 59 Pirfenidone 59 Phenoptin 59 phase IIb 59 CG# [003] 59 hematological cancers 59 gastro intestinal inflammation 59 palifosfamide 59 sapacitabine CYC# 59 Indibulin 59 familial amyloidotic polyneuropathy FAP 59 ASONEP 59 solithromycin 59 bafetinib 59 Hematide ™ 59 Virulizin R 59 Pertuzumab 59 MPS IVA 59 neratinib 59 metastatic colorectal 59 imatinib Gleevec ® 59 Pivotal Phase III 59 antagomirs 59 Phase 2a trial 59 small molecule Hedgehog 59 PEGylated Fab fragment 59 Ofatumumab 59 orally dosed 59 peripherally acting 59 adecatumumab 59 tramiprosate Alzhemed TM 59 pharmacological chaperone 59 Marqibo TM 59 NEUGENE 59 cabozantinib 59 Anidulafungin 59 HRPC 59 cutaneous T cell 59 menadione 59 SinuNase ™ 59 cutaneous T 59 TRV# [001] 59 brostallicin 59 angiogenesis inhibition 59 DPX Survivac 59 oral anticancer 59 gastrointestinal stromal tumors GIST 59 aurora kinase 59 potent antiproliferative 59 Phase #/#a 59 Phase 2b trial 59 Tß4 59 Oxytrex TM 59 talabostat 59 Phase 2b study 59 phase III isavuconazole 59 CTAP# Capsules 59 Vascular Endothelial Growth 59 Avicena 59 ASA# 59 PDE# 59 Phenserine 59 Chemophase 59 NNR Therapeutics 59 ularitide 59 Insegia 59 Phase 2b clinical 59 MOR# 59 Teriflunomide 59 dasatinib Sprycel ® 59 cancer vaccine Norelin 59 antiproliferative effects 59 belinostat 59 Genasense R oblimersen 59 personalized cellular immunotherapy 59 SGLT Inhibitors 59 Bayer HealthCare Onyx Pharmaceuticals 59 Zalypsis 59 oral antiviral 59 Onalta 59 antibody MAb 59 ATL# [002] 59 bevacizumab Avastin ® 59 ZYBRESTAT TM 59 Diamyd R 59 telomerase inhibitor drug 59 GMX# 59 docetaxel Taxotere R 59 DermaVir Patch 59 immunotherapeutic 59 accumulate preferentially 59 antisense inhibitors 59 Genasense ® 59 olaparib 59 inhaled formulation 59 Arimoclomol 59 ART# 59 Thiovir 59 molecular chaperone amplification 59 HepeX B 59 Onalta ™ 59 evaluating tivozanib 59 defensin mimetic antibiotic 59 Regado 59 tivozanib 59 Bendavia 59 unique alkylating agent 59 efaproxiral 59 investigational compound 59 hematologic malignancies 59 teplizumab 59 oral picoplatin 59 hypereosinophilic syndrome 59 VEGF inhibitors 59 BLP# Liposome Vaccine 59 VNP#M 59 resistant ovarian cancer 59 HepeX B TM 59 amrubicin 59 ELND# 59 anticancer therapeutics 59 Telintra 59 molecularly targeted 59 Immunotherapeutic 59 Altropane 59 TAFA# 59 CUDC 59 CDK inhibitor 59 investigational compounds 59 haematological cancers 59 Phase 2a Clinical Trial 59 Combination REOLYSIN R 59 Gefitinib 59 AeroLEF TM 59 Locteron ® 59 Bucindolol 59 ProSavin 59 metastatic renal cell carcinoma 59 immunomodulating 59 refractory multiple myeloma 59 mTOR inhibitor 59 L DOS# 59 dose escalation Phase 59 Aurora kinase inhibitors 59 HDAC Inhibitor 59 Rebif ® 59 novel VDA molecule 59 solid tumors 59 Viprovex TM 59 Celsion Corporation 59 Inotek Pharmaceuticals Corporation 59 neovascular diseases 59 mRCC 59 carfilzomib 59 metastatic liver 59 Civacir 59 tumor subtypes 59 Diabetic Macular Edema 59 sodium glucose transporter 59 oral gallium 59 Onco TCS 59 omacetaxine mepesuccinate 59 thymalfasin 59 BrachySil 59 bardoxolone methyl 59 deforolimus 59 Survivin 59 small molecule activators 59 Dacogen decitabine 59 Familial Adenomatous Polyposis FAP 59 Ozarelix 59 MIS# 59 ANYARA 59 CDK cyclin dependent 59 incyclinide 59 pharmacokinetic PK 59 AZX# 59 TRX1 59 Liprotamase 59 relapsed AML 59 nanoviricides 59 Ramoplanin 59 ALS #-# 59 Neovascular AMD 58 castration resistant prostate cancer 58 GED aPC 58 glufosfamide 58 AA Amyloidosis 58 Androxal ® 58 keloid scarring 58 Stedivaze 58 iSONEP 58 CLORETAZINE TM VNP#M 58 OncoVEX 58 anticancer compounds 58 perifosine 58 acadesine 58 MOZOBIL 58 CCR2 58 carbohydrate polymer 58 Teplizumab 58 HCV protease 58 SPRYCEL ® 58 Uricase PEG 58 Phase 1b clinical 58 Atu# 58 renin inhibitor 58 Acute Myeloid Leukemia AML 58 Fodosine 58 ZOLINZA 58 ESBA# 58 GRNVAC1 58 Indaflex TM 58 brentuximab vedotin SGN 58 Kinase Inhibitor 58 perifosine KRX 58 ALTROPANE 58 lomitapide 58 biliary tract cancer 58 lintuzumab 58 drug ISA# 58 Vion Pharmaceuticals 58 systemically administered 58 Exherin 58 Kahalalide F 58 Abiraterone acetate 58 metastatic castration resistant 58 TELCYTA 58 glioblastoma multiforme GBM 58 targeted kinase inhibitor 58 Phase 2a clinical trials 58 #I TM# 58 PF # [001] 58 endothelin receptor 58 adipiplon 58 Manja Bouman CEO 58 renin inhibitors 58 Presents Preclinical Data 58 midstage clinical 58 DDP# 58 PI3K inhibitors 58 Diabetic Nephropathy 58 HDL Mimetic Peptide 58 preclinical efficacy 58 TYZEKA 58 sigma receptors 58 veltuzumab 58 Adnectin 58 HuMax CD# 58 S/GSK# 58 Myelodysplastic Syndrome MDS 58 PROSTVAC TM 58 Etubics 58 sitaxsentan 58 Anticalin R 58 Zenvia Phase III 58 Phase III Clinical Trials 58 LHRH antagonists 58 Proellex TM 58 Zingo TM 58 palifosfamide Zymafos TM 58 PDE# inhibitors 58 polymerase inhibitor 58 SGLT inhibitors 58 muscarinic receptor agonist 58 Xcytrin R 58 Leber Hereditary Optic Neuropathy 58 Tarceva TM 58 Amplimexon 58 Octreotide 58 Aryplase 58 refractory NSCLC 58 EGFR HER2 58 Liprostin 58 PRX# 58 EGS# 58 Diabetic Macular Edema DME 58 APF# 58 mGluR5 negative 58 BRIM3 58 cancer immunotherapy 58 selective inhibition 58 therapeutic monoclonal antibodies 58 Novel Oral 58 hypoxia inducible factor 58 cardiac muscle contractility 58 ImmunoVEX HSV2 58 MYDICAR ® 58 siRNA therapeutic 58 non alcoholic steatohepatitis 58 ThermoDox ® 58 alvimopan 58 ABL inhibitor